Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 D769Y |
Gene Variant Detail | |
Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 D769Y | malignant peripheral nerve sheath tumor | predicted - sensitive | HER2 Inhibitor | Lapatinib | Case Reports/Case Series | Actionable | In a clinical case study, Tykerb (lapatinib) treatment resulted in clinical improvements, partial tumor size reduction, and metabolic response in a patient with neurofibroma/schwannoma hybrid nerve sheath tumor harboring ERBB2 (HER2) D769Y (PMID: 32017710). | 32017710 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | gastroesophageal junction adenocarcinoma | predicted - resistant | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). | 29420467 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Tarloxotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tarloxotinib (TRLX) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). | 29967253 |
ERBB2 D769Y | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | breast cancer | sensitive | HER2 Inhibitor | Neratinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880). | 23220880 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 | |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). | 29967253 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sapitinib (AZD8931) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). | 29967253 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tagrisso (osimertinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 | |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tagrisso (osimertinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). | 29967253 | |
ERBB2 D769Y | urinary bladder cancer | predicted - resistant | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with bladder cancer harboring both ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). | 29420467 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). | 29967253 |
ERBB2 D769Y | breast cancer | sensitive | HER2 Inhibitor | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). | 23220880 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 | |
ERBB2 D769Y | Advanced Solid Tumor | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y demonstrated resistance to Herceptin (trastuzumab) treatment in culture (PMID: 29967253). | 29967253 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Recruiting | USA | 0 |
NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |